Description
GDMT optimisation with SGLT2 inhibitors, sacubitril/valsartan, LVAD, and heart transplant referral criteria. Updated per 2022 AHA/ACC Heart Failure Guidelines.


₹42.00
Evidence-based management of HFrEF, HFpEF, mechanical support and advanced therapies.
GDMT optimisation with SGLT2 inhibitors, sacubitril/valsartan, LVAD, and heart transplant referral criteria. Updated per 2022 AHA/ACC Heart Failure Guidelines.
You must be logged in to post a review.
Reviews
There are no reviews yet.